DOSING USED IN PHASE 3 STUDIES In the most recent studies from the TRIUMPH programme (Phase 3) , retatrutide was administered as follows: Route: Subcutaneous Frequency: Once weekly Study duration: Approximately 68 weeks Recommended Dosage (Clinical Research Escalation Model) Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability
Cell-assay potency values cannot be translated directly into a weekly human dose
This is why it gives a stronger effect
These molecules are more resistant to degradation by DPP-4, which results in a prolonged half-life in comparison with endogenous GLP-1
Researchers studying how fast semaglutide works typically observe appetite changes within the first week, with clinically meaningful weight loss emerging by weeks 4 to 8
Interestingly, homocysteine levels have been positively associated with serum GGT, suggesting elevations in homocysteine may at least partly be due to increased shunting toward glutathione synthesis in response to increased GSH demands, though this has not been proven as of yet